ClinicalTrials.Veeva

Menu

Renal Denervation Therapy in Hypertensive Patients Undergoing A-Fib Ablation

S

Siva Mulpuru

Status

Terminated

Conditions

Hypertension
Atrial Fibrillation

Treatments

Procedure: AF ablation with Renal Denervation
Procedure: AF ablation alone

Study type

Interventional

Funder types

Other

Identifiers

NCT01952743
12-009062

Details and patient eligibility

About

We propose a pilot study to assess safety and benefit of renal artery ablation at the time of planned atrial fibrillation ablation.

Full description

Symptomatic atrial fibrillation (AF) refractory to anti-arrhythmic drugs is commonly treated with ablation therapy. Pulmonary vein isolation along with additional substrate medication is commonly performed during ablation procedures is associated with 60-80% success rate for maintenance of sinus rhythm. After AF ablation hypertension (HTN) is a strong predictor for recurrence of atrial fibrillation. Drug resistant hypertension can be effectively treated with catheter based renal denervation therapy. Our primary hypothesis is concomitant renal denervation therapy along with AF ablation is associated with improvement in success rates of AF ablation along with adequate control of blood pressure. The specific objectives of this study are to prospectively compare success rates, time to AF recurrence, AF burden and blood pressure controls in patients randomized to concomitant renal denervation arm when compared to patients with AF ablation alone.

Enrollment

3 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  1. Paroxysmal and Persistent Atrial Fibrillation refractory eligible for AF ablation as per HRS/ECAS/EHRA consensus statement.[23] Paroxysmal AF is defined as two or more episodes of AF lasting less than 7 days in duration during the last 6 months before enrollment. Persistent AF is defined as AF lasting more than 7 days or requiring cardioversion for termination.
  2. Hypertension (>140/80 mm Hg) on treatment with at least 1 hypertensive medication.
  3. GFR >60ml/dl using Cockcroft- Gault equation

Exclusion criteria

  1. Secondary causes of hypertension
  2. Severe renal artery stenosis or dual renal arteries
  3. Congestive heart failure with NYHA class III or IV status
  4. EF< 35%
  5. LA Diameter >6 cm
  6. Previous AF ablation
  7. Previous renal artery stent or angioplasty
  8. Severe contrast allergy
  9. Inability to give informed consent
  10. Solitary kidney

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Factorial Assignment

Masking

None (Open label)

3 participants in 2 patient groups

AF Ablation alone
Active Comparator group
Description:
Clinical AF ablation performed as deemed appropriate by operator
Treatment:
Procedure: AF ablation alone
AF ablation with Renal Denervation
Experimental group
Description:
Renal denervation performed using the same ablation catheter after clinical AF ablation
Treatment:
Procedure: AF ablation with Renal Denervation

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems